Volume Watcher retweeted
Replying to @rayjaymartin @LausenAllan
$TNXP
Yes indeed. Seems CEO at some bad ass's advise "intentionally" let big boys to get in ah. But nobody can change the valuation it should be given to the approval drug and its future commercial potentials.
Next week, we double regardless today's ah price.
3-4 digits we come!
Volume Watcher retweeted
$TNXP
The website literally crashed, too many people clicking.
LOL
📉 The sudden intraday drop in $TNXP from 65 to 14 does not necessarily reflect a decline in the company’s fundamentals, but may be the result of fund share exchanges or short squeeze–related movements.
📊 Remember: such fluctuations are often temporary, strong catalysts are coming, and don’t let them take your shares.
#TNXP #Stocks #ShortSqueeze
Volume Watcher retweeted
$TNXP FDA decision on TNX-102 SL arrives tomorrow with Fast Track status, no AdCom, a positive Phase 3, and an estimated $125M cash runway, positioning it to be the first new fibromyalgia therapy in over 16+ years.
The science is done, the path is clear, approval could be hours away, stay positive, LONG AND STRONG.
Volume Watcher retweeted
Attention Fibromyalgia sufferers, are you aware that TOMORROW the FDA is almost sure to give Tonix Pharmaceutical the Approval for this new Miracle Drug.
Non-Opiod, helps with Sleep, PTSD, Stress as well.
Buy TNXP b4 approval Friday.
@TonixPharma
$tnxp
Volume Watcher retweeted
Fun fact, when the PDUFA date for #Tonnya, the fibromyalgia drug of @TonixPharma , was set $TNXP spiked to $130
Currently $46 and 25% of their $400M MC is CA$H
The global fibromyalgia treatment market is projected to reach $4.13 billion by 2032
Replying to @TonixPharma
@TonixPharma ➡️ $TNXP
#Tonmya is poised to be the first fibromyalgia, treatment drug to be approved in more than 15 years and it’s a MASSIVE MARKET
PDUFA date ➡️ August 15,2025
🔔 Major Catalyst for $APLS
📅 Tomorrow, July 28: FDA decision on expanding EMPAVELI use for rare kidney diseases (C3G & IC-MPGN)
🔬 Approval probability: 85%+, backed by strong Phase 3 data
✅ Granted Priority Review status
💥 Approval could open a new market and drive the stock up +30%
#APLS #FDA #Biotech #Pharma #Stocks #Investing #nasdaq
FDA Approves $APLS Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
1
511
$APLS
I believe they’re using a deliberate tactic in their announcement , a form of suspense or buildup. 😅
2
824
🧠 Key Watch for $BIIB
💊 Drug: LEQEMBI® for Alzheimer’s disease
📅 FDA decision: July 31, 2025
🔬 Approval probability: 99%
✅ Full approval could expand access and boost insurance coverage
📈 A major catalyst for Biogen’s neurology pipeline and revenue growth
#BIIB #FDA #Alzheimers #Biotech #Pharma #Investing #nasdaq
269
🚨 On Watch: $REGN
🧬 Promising cancer therapy: Odronextamab
📅 Key FDA decision: July 30, 2025
🎯 Indication: Relapsed/refractory follicular lymphoma
🔬 Approval probability: 85%+ based on strong clinical data
📈 A green light could mark a major step for REGN in oncology and offer a CAR-T alternative
#REGN #FDA #Oncology #Biotech #Pharma #Stocks #nasdaq
526
Critical anticipation for $APLS as the FDA decision approaches on July 28 regarding the expanded use of EMPAVELI to treat rare kidney diseases.
✅ An approval would mean:
– The first approved treatment for these conditions
– Access to an entirely new market
– Potential stock surge of 30%+
Will this mark a new breakout for the stock?
#Biotech #FDA #Stocks #Pharma #Nasdaq
🚨 Positive News Alert!!
🔬 $TNXP Tonix announces promising results for its TNX‑801 vaccine against orthopoxviruses:
✅ Single dose provides strong and long-lasting protection
🦠 Up to 100,000 times less virulent than traditional smallpox vaccines
🧫 Proven efficacy in animal models (monkeys, rabbits, mice)
🌍 A promising candidate for combating mpox and future outbreaks
#TNXP #Biotech #Vaccines #Mpox #FDA
Tonix Pharmaceuticals has been added to the Russell 3000 Index, with automatic inclusion in the Russell 2000, effective June 30, 2025, as part of the 2025 Russell Index reconstitution.
#TNXP #Russell2000 #Biotech #Pharma #Stocks #SmallCaps #RussellReconstitution
1
1
254
Volume Watcher retweeted
Great article on $TNXP, explaining that if their company gets FDA approval of its new fibromyalgia treatment on August 15th, the stock price could EXPLODE to an average price of $585 and a potential high of $1,100
seekingalpha.com/article/479…
📈 $QMMM is showing a positive setup with buy signals across most indicators.
A breakout above the ~$1.12–1.15 resistance zone could open the door for a move toward $1.23–1.27.
#QMMM #NASDAQ #TechnicalAnalysis #SmallCaps #StockMarket #Trading
2
493
📉 $VYNE short-term outlook: A moderate rebound remains possible as long as the price holds above the ~$0.90 support.
📈 Mid-term: A breakout above the ~$0.96–1.04 zone is needed to confirm a bullish reversal.
#VYNE #NASDAQ #BiotechStocks #TechnicalAnalysis #StockMarket #Trading
1
2
734
📈 $TPET is showing positive short-term momentum with RSI around 56.
Most technical indicators (MACD, moving averages) signal a clear bullish setup.
The overall pattern suggests a potential upward continuation — as long as key support holds.
🚀 A breakout above $1.78 could open the door to new highs.
#TPET #TechnicalAnalysis #NASDAQ #OilStocks #Trading #StockMarket
163
📉 $HOLO is currently trading between a support level near $6.48 and short-term resistance around $6.89.
The RSI hovers around 46, suggesting a potential short-term rebound in the coming days.
However, the trend remains neutral to bearish unless higher moving averages are broken and key resistance levels are cleared.
#HOLO #NASDAQ #USstocks #TechnicalAnalysis #Trading #StockMarket
805








